{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:07:52Z","timestamp":1788826072482,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.htct.2026.106257","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T01:02:49Z","timestamp":1771722169000},"page":"106257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3661-2581","authenticated-orcid":false,"given":"Musab MA","family":"Omar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed A","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-8009","authenticated-orcid":false,"given":"Denise E.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.htct.2026.106257_bib0001","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.htct.2026.106257_bib0002","first-page":"1","article-title":"Future approaches for treating chronic myeloid leukemia: CRISPR therapy","volume":"10","author":"Vuelta","year":"2021","journal-title":"Biology (Basel)"},{"issue":"2","key":"10.1016\/j.htct.2026.106257_bib0003","first-page":"1","article-title":"Combined effects of 2-methoxyestradiol (Hypoxia-Inducible Factor 1\u03b1 Inhibitor) and dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on chronic myelocytic leukemia cells","volume":"10","author":"Zhang","year":"2021","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.htct.2026.106257_bib0004","first-page":"1","article-title":"The progression of chronic myeloid leukemia to myeloid sarcoma: a systematic review","volume":"14","author":"Hadia","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.htct.2026.106257_bib0005","first-page":"1","article-title":"Quantitative prediction of longterm molecular response in TKI treated CML \u2013 Lessons from an imatinib versus dasatinib comparison","volume":"8","author":"Glauche","year":"2018","journal-title":"Nat Sci Rep"},{"issue":"1","key":"10.1016\/j.htct.2026.106257_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells10010117","article-title":"Chronic myeloid leukemia: a model disease of the past, present and future","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.htct.2026.106257_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06782-9","article-title":"The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib","volume":"20","author":"G Lindstr\u00f6m","year":"2020","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.htct.2026.106257_bib0008","first-page":"7787","article-title":"Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence","volume":"25","author":"Ciftciler","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.htct.2026.106257_bib0009","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/17512433.2021.1894129","article-title":"Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies","volume":"14","author":"Wang","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.htct.2026.106257_bib0010","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation","volume":"97","author":"Liu","year":"2021","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.htct.2026.106257_bib0011","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","article-title":"Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"113","author":"Lee","year":"2021","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1016\/j.htct.2026.106257_bib0012","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474086.2021.1990034","article-title":"Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"14","author":"Malik","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"18","key":"10.1016\/j.htct.2026.106257_bib0033","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.htct.2026.106257_bib0013","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.2021014689","article-title":"Asciminib: a new therapeutic option in chronic-phase CML with treatment failure","volume":"139","author":"Yeung","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.htct.2026.106257_bib0019","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2026.106257_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.htct.2026.106257_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2022.103580","article-title":"Development of asciminib, a novel allosteric inhibitor of BCR-ABL1","volume":"171","author":"R\u00e9a","year":"2022","journal-title":"Crit Rev Oncol\/Hematol."},{"key":"10.1016\/j.htct.2026.106257_bib0016","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11899-019-00546-4","article-title":"Towards a personalized treatment of patients with chronic myeloid leukemia","volume":"14","author":"Rabian","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"10.1016\/j.htct.2026.106257_bib0017","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.htct.2026.106257_bib0018","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/cancers15041045","article-title":"Toxicity of asciminib in real clinical practice: analysis of side effects and cross-toxicity with tyrosine kinase inhibitor","volume":"15","author":"P\u00e9rez-Lamas","year":"2023","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.htct.2026.106257_bib0022","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.htct.2026.106257_bib0023","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14740338.2021.1969360","article-title":"Fatigue and its management in cancer patients undergoing VEGFR-TKI therapy","volume":"21","author":"Takahashi","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.htct.2026.106257_bib0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.htct.2026.106257_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01309-0","article-title":"A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase","volume":"15","author":"Garc\u00eda-Guti\u00e9rrez","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.htct.2026.106257_bib0029","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s43042-022-00248-2","article-title":"Chronic myeloid leukemia: cytogenetics and molecular biology\u2019s part in the comprehension and management of the pathology and treatment evolution","volume":"23","author":"Benchikh","year":"2022","journal-title":"Egypt J Med Hum Genet"},{"key":"10.1016\/j.htct.2026.106257_bib0030","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1182\/blood-2023-186773","article-title":"ASC4START and ASC4FIRST: two ongoing phase 3 trials investigating asciminib monotherapy as first-line therapy versus tyrosine kinase inhibitors in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase","volume":"142","author":"Hochhaus","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.htct.2026.106257_bib0031","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/antibiotics12040650","article-title":"Inhibitors of ATP synthase as new antibacterial candidates","volume":"12","author":"Mackieh","year":"2023","journal-title":"Antibiotics"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:23:59Z","timestamp":1788823439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137926000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2531137926000040"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2026.106257","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2026.106257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"106257"}}